<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03951571</url>
  </required_header>
  <id_info>
    <org_study_id>IRB1902197-8</org_study_id>
    <nct_id>NCT03951571</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Anlotinib in Adjuvant Therapy for High-grade Soft Tissue Sarcoma</brief_title>
  <official_title>Efficacy and Safety of Anlotinib Hydrochloride (AL3818) in Postoperative Adjuvant Therapy for High-grade Soft Tissue Sarcoma -- A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Trail</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of Anlotinib Hydrochloride Capsule combined with Best
      Supportive Therapy in the adjuvant treatment of patients with high-grade soft tissue sarcoma
      after operation, as compared with placebo combined with Best Supportive Therapy.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 13, 2019</start_date>
  <completion_date type="Anticipated">August 13, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 13, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DFS</measure>
    <time_frame>2 years</time_frame>
    <description>Disease Free Survival</description>
  </primary_outcome>
  <primary_outcome>
    <measure>1-year and 2-year DFR</measure>
    <time_frame>2 years</time_frame>
    <description>1-year and 2-year disease-free survival rates</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>2 years</time_frame>
    <description>Overall Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LRFS</measure>
    <time_frame>2 years</time_frame>
    <description>Local Recurrence Free Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DMFS</measure>
    <time_frame>2 years</time_frame>
    <description>Distant Metastasis Free Survival</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Soft Tissue Sarcoma Adult</condition>
  <condition>High Grade Sarcoma</condition>
  <arm_group>
    <arm_group_label>Anlotinib Gruop</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anlotinib Hydrochloride</intervention_name>
    <description>Before breakfast, take an Anlotinib hydrochloride placebo once a day, 12 mg (1 pill) at a time. Continuous oral administration for two weeks and stop for one week. Three weeks (21 days) for a treatment cycle. The total treatment cycles is six.</description>
    <arm_group_label>Anlotinib Gruop</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Before breakfast, take an placebo once a day, 1 pill at a time. Continuous oral administration for two weeks and stop for one week. Three weeks (21 days) for a treatment cycle. The total treatment cycles is six.</description>
    <arm_group_label>Placebo Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1.High-grade soft tissue sarcoma patients without standard adjuvant chemotherapy after
             surgery. Mainly includes: liposarcoma(except for Myxoid/round cell liposarcoma),
             leiomyosarcoma, malignant peripheral nerve sheath tumor, fibrosarcoma, clear cell
             sarcoma, alveolar soft part sarcoma, angiosarcoma, epithelioid sarcoma, malignant
             solitary fibrous tumor and so on. Except for rhabdomyosarcoma, gastrointestinal
             stromal tumors, dermatofibrosarcoma protuberans, Ewing sarcoma/primary neuroectodermal
             tumors, inflammatory myofibroblastoma, malignant mesothelioma.

             2.The postoperative microscopic margin was negative and the pathological diagnosis was
             high-grade soft tissue sarcoma. The diagnosis was completed by pathologists, and the
             pathological specimens were confirmed by the research center.

             3.The age is ≥18 years old, the ECOG score is ≤2, and the estimated survival time is
             more than 3 months.

             4.Examinations meet the following criteria:

               1. Blood routine examination: HB ≥ 100g/L(no blood transfusion within 14 days); ANC
                  ≥ 1.5×10^9 /L; PLT ≥ 80×10^9 /L

               2. Other examinations: Cr ≤ upper limit of normal value (ULN); BIL ≤ ULN; ALTAST ≤
                  1.5 × ULN (for patients with liver metastasis ≤ 5 × ULN); fasting triglyceride
                  ≤3.0mmol/L; fasting cholesterol ≤7.75mmol/L;

               3. Doppler ultrasound assessment: LVEF ≥ 50%. 5. Females should agree to use
                  contraceptives (such as intrauterine devices (IUD), birth control pills or
                  condoms) during the study period and 6 months after the end of study and the
                  serum or urine pregnancy test was negative within 7 days prior to study
                  enrollment and must be non-lactating; Males should agree to use contraception
                  during the study period and within six months after the end of the study period.

             6.Patients should participate in the study involuntarily, sign the informed consent,
             and have good compliant and agree to be followed up.

        Exclusion Criteria:

          -  1. Patients who have received targeted therapy of vascular endothelial growth
             inhibitors, such as sunitinib, sorafenib, bevacizumab, imatinib, famitinib and
             apatinib, etc.

             2. Patients who have malignant tumors previously or concomitantly, except for cured
             skin basal cell carcinoma and cervical carcinoma in situ; 3. Those who participated in
             other drug clinical trials within 4 weeks; 4. Those who received chemotherapy within 4
             weeks. 5. Those who received anticancer therapy previously and have toxic reactions of
             NCI-CTC AE grade &gt; grade 1 now; 6. Patients who have multiple factors affecting oral
             medication (such as inability to swallow, Post-gastrointestinal resection, chronic
             diarrhea and intestinal obstruction, etc.); 7. Patients who have brain metastases,
             spinal cord compression, cancerous meningitis, or screening CT or MRI findings of
             brain or pia mater disease.

             8. Patients have any serious or uncontrolled disease, such as:

               1. Unstable angina pectoris, symptomatic congestive heart failure, myocardial
                  infarction within 6 months before randomization, severe uncontrolled arrhythmia;
                  patients with unsatisfactory blood pressure control (systolic blood pressure &gt;
                  140 mmHg, diastolic blood pressure &gt; 90 mmHg);

               2. Active or uncontrolled severe infections;

               3. Liver diseases such as cirrhosis, decompensated liver disease and chronic active
                  hepatitis;

               4. Poor control of diabetes mellitus (FBG &gt; 10mmol/L);

               5. Urinary routine examination showed that urinary protein (++) and confirmed by the
                  24-hour urinary protein quantification(&gt;1.0 g); 9. Long-term unhealed wound or
                  fracture 10. Patients with bleeding tendency (e.g. active gastrointestinal ulcer)
                  or treated with anticoagulants or vitamin K antagonists such as warfarin, heparin
                  or their analogues.

             11. Arterial or venous thrombosis occurred before the first dose, such as
             cerebrovascular accidents (including transient ischemic attacks), deep vein
             thrombosis, and pulmonary embolism.

             12. Those who have a history of psychotropic drug abuse and are unable to get rid of
             or have mental disorders.

             13. Those who have a history of immunodeficiency, including HIV positive or other
             acquired, congenital immunodeficiency disorders, or organ transplantation.

             14. According to the investigator's assessment, there are serious concomitant diseases
             that endanger the safety of the patient or affect the patient's completion of the
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wangjun Yan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wangjun Yan, M.D.</last_name>
    <phone>+86 18121299399</phone>
    <email>yanwj@fudan.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chunmeng Wang, M.D.</last_name>
    <phone>+86 18017317143</phone>
    <email>cmwang1975@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cancer Hospital of Sun Yat-sen</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jing Wang, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Jing Wang, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yunnan Cancer Hospital</name>
      <address>
        <city>Kunming</city>
        <state>Yunnan</state>
        <zip>650118</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhengjiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Tao Li, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Tao Li, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Wangjun Yan, M.D.</last_name>
      <phone>18121299399</phone>
      <email>yanwj@fudan.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Chunmeng Wang, M.D.</last_name>
      <phone>18017317143</phone>
      <email>cmwang1975@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Wangjun Yan, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chunmeng Wang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Six People's Hospital Affiliated to Shanghai Jiao Tong University</name>
      <address>
        <city>Shanghai</city>
        <zip>200233</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yang Dong, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Yang Dong, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 10, 2019</study_first_submitted>
  <study_first_submitted_qc>May 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2019</study_first_posted>
  <last_update_submitted>May 14, 2019</last_update_submitted>
  <last_update_submitted_qc>May 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Wangjun Yan</investigator_full_name>
    <investigator_title>Director, Head of Musculoskeletal Oncology, Principal Investigator, Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

